Analyst firms · BofA Securities · TSBX
BofA Securities TSBX price target and rating history
Turnstone Biologics Corp. (TSBX) · Health Care
BofA Securities rates Turnstone Biologics Corp. (TSBX) Underperform with a $18 price target, as of its latest action on Nov 15, 2024. It has published 3 rating actions on TSBX since August 2023, including 0 upgrades and 2 downgrades.
- Current rating
- Underperform
- Price target
- $18
- Median target, all firms
- Too few
- Actions on TSBX
- 3
Every BofA Securities rating on TSBX
- Nov 15, 2024
- Oct 14, 2024
- Aug 15, 2023
Questions about BofA Securities and TSBX
- What is BofA Securities's price target for TSBX?
- BofA Securities's latest stated price target for Turnstone Biologics Corp. (TSBX) is $18, from its action on Aug 15, 2023.
- What is BofA Securities's rating on TSBX?
- BofA Securities rates TSBX Underperform, a bearish rating, as of Nov 15, 2024.
- When did BofA Securities last change its view on TSBX?
- On Nov 15, 2024, BofA Securities downgrades to Underperform from Neutral.
All BofA Securities ratingsTSBX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.